Schlintl, Verena
Huemer, Florian
Rinnerthaler, Gabriel
Melchardt, Thomas
Winder, Thomas
Reimann, Patrick
Riedl, Jakob
Amann, Arno
Eisterer, Wolfgang
Romeder, Franz
Piringer, Gudrun
Ilhan-Mutlu, Aysegül
Wöll, Ewald
Greil, Richard
Weiss, Lukas
Article History
Received: 25 August 2021
Accepted: 15 December 2021
First Online: 10 January 2022
Declarations
:
: The analysis was approved by the ethics committee of the provincial government of Salzburg (415-EALL/5/39–2019), the ethics committee of the Medical University of Vienna (2000/2020) and the ethics committee of the Medical University of Innsbruck (1304/2019).
: Not applicable.
: A.A., W.E., T.M., G.P., P.R., J.R., V.S. and T.W. have nothing to disclose; R.G. reports personal fees from Merck, BMS and MSD outside the submitted work; F.H. reports support from Lilly, Pierre Fabre, Amgen, Servier, Pfizer, BMS, Roche, Merck and Pharmamar outside the submitted work; A.I.M. reports participation in advisory boards from MSD, BMS and Servier, received lecture honoraria from Eli Lilly, MSD and Servier, is the local PI for clinical trials sponsored by BMS and Roche and received travel support from BMS and Roche; G.R. reports personal fees from Roche, BMS and MSD outside the submitted work; F.R. reports travel support from Amgen, Eli-Lilly and Roche outside the submitted work; L.W. reports personal fees from Amgen, Bayer, BMS, Lilly, Merck, MSD, Novocure, Nordic Pharma, Pierre Fabre, Roche, Sanofi and Takeda outside the submitted work; E.W. reports personal fees from AstraZeneca, Roche, MSD and BMS outside the submitted work.